DoubleBlind: A collage of a face with three small hands around the face.

This Company is Developing a Drug Based on Ibogaine for the Opioid Crisis

18-MC allegedly puts an end to unhealthy cravings while sparing patients a brutal trip

Troy Farah // Sept. 14, 2019

DoubleBlind is devoted to fair, rigorous reporting by leading experts and journalists in the field of psychedelics. Read more about our editorial process and fact-checking here.

A Canadian company will announce on Monday (September 16) the development of a synthetic drug based on the chemical structure of ibogaine, a psychedelic with a long history of ceremonial use.  Mind Medicine Inc. (“Mindmed”) is betting that 18-MC (18-methoxycoronaridine) will be a powerful tool to fight addiction and opioid use disorder. 

The potent dissociative drug ibogaine occurs naturally in a few plants in Africa and South America, but it’s unique among psychedelic alkaloids. While research is still premature, after a single ingestion ibogaine can allegedly snap someone out of the throes of addiction.

Mindmed obtained the rights to 18-MC from the California-based pharmaceutical startup Savant HWP Inc., through an acquisition merger. Savant’s researchers and drug developers will join Mindmed as part of their clinical development team.

DoubleBlind presents: How to grow mushrooms online course. Let's Shroom!

The National Institute on Drug Abuse (NIDA) previously funded Savant’s 18-MC drug development program to the tune of $6.7 million in 2012, however, the program included only one clinical trial. Mindmed is not only conducting Phase II FDA-approved trials using 18-MC to target opioid use disorder, but also plans to explore LSD, psilocybin, and ketamine to treat mental health. 

In Bwiti, a religious subculture originating in West Central Africa, ibogaine is a sacrament used in healing ceremonies. The trance-like state that results from eating the dried root bark of iboga, the perennial rainforest shrub that contains ibogaine, is considered “a crucial moment in Bwiti therapy,” according to recent research published in the journal Mental Health, Religion & Culture.

Since at least 1955, researchers have been exploring the drug’s usefulness in treating substance use disorders. Preliminary research in rodents and humans suggests ibogaine can rapidly eradicate cravings for alcohol, cocaine, nicotine, and opioids—but how the drug accomplishes this remains poorly understood. While ibogaine has yet to see mainstream clinical use, some people have opened alternative wellness clinics in places where the drug is legal, such as Mexico or New Zealand. In Canada, ibogaine is legal to possess, but not to sell.

However, unlike most psychedelics, ibogaine is known to be toxic to the heart, sometimes even days or weeks after administration, which can be life-threatening if patients are not properly screened before and after use. Fatalities are rare, but not unheard of, while in 2015, doctors at the Medical University of Vienna recommended that people who take the drug should be under constant medical supervision.

18-MC does not seem to have these same toxic issues. In fact, it allegedly doesn’t cause the intense hallucinations and discomfort ibogaine is known for, yet still has the same anti-addictive effects. In Savant’s sole Phase I clinical trial, they found 18-MC was safe in humans. While in Bwiti belief, ibogaine’s hallucinations are central to healing, that may not be the case with 18-MC’s ability to reduce drug cravings, which may give the synthetic broader appeal.

DoubleBlind's newest course: Using Psychedelics for Growth.

“We believe that hallucinogenic therapies also have great merit and benefits for treating addiction, but undergoing a ‘psychedelic trip’ might be a daunting proposition to some patients,” Jamon R. Rahn, Mindmed co-founder and director, said in a press release. “After successful clinical trials, we intend for our non-hallucinogenic medicines derived from psychedelics to be prescribed by physicians and for patients to pick them up at their local pharmacy, greatly increasing the economics and accessibility of such medicines.”

Those clinical trials are slated to begin next year. In a phone call, Rahn told DoubleBlind that Mindmed will be exploring other non-hallucinogenic psychedelics, as well as potentially exploring other applications for 18-MC. It’s been shown to treat leishmaniasis, a parasitic disease spread by sandflies.

“We’ve also been approached to look at nicotine dependence related to the recent teen vaping crisis,” Rahn said. But because psychedelic research in the United States is still “fringe,” he added, Mindmed is working in Canada. “The traditional biopharmaceutical or neural pharmaceutical investors are just not really interested in the space at the moment,” he said. “Canada understands that [even though] something might appear to be fringe, it could become a very big market.”

Troy Farah is an independent journalist from Southwest California. His reporting on drug policy and science has appeared in WIRED, The Guardian, Undark, Discover Magazine, VICE and more. He co-hosts the drug policy podcast Narcotica. Follow him on Twitter.

Save money and time with DoubleBlind's how to grow shrooms course. Let's Shroom!

Georgia Love is a Vancouver based photographer, content creator, and stylist whose work shows female sexuality through empowerment and her signature glow-style. Her work has been published in both Forbes and Yahoo Finance. Follow her on Instagram.

We have a small favor to ask. In 2020, more than five million readers like you visited DoubleBlind’s website. Many of them are suffering and simply seeking trusted information on how to use psychedelics to heal.

We started DoubleBlind two years ago at a time when even the largest magazines and media companies were cutting staff and going out of business. Friends and family said we were crazy. But we did it anyway, because we believe in it—deeply. We believe in the value of good journalism. And we believe in the extraordinary potential of psychedelics to reduce suffering. At the time we made a commitment: we will never have a paywall, we will never rely on advertisers we don’t believe in to fund our reporting, and we will always be accessible via email and social media to support people for free on their journeys with plant medicines.

To help us do this, if you feel called and can afford it, we ask you to consider making a monthly donation to DoubleBlind, starting at $1. In exchange, you’ll be invited to a monthly Zoom call with DoubleBlind’s co-founders, Shelby Hartman and Madison Margolin, where they’ll answer any questions you have about the psychedelic movement or your own journey with psychedelics. These Zoom calls also include special guests, some of the people who we love and respect most in the psychedelic space. Together, we brainstorm, collaborate, dialogue, and, simply, commune. Either way, please know that we value you as a member of our community. Make a gift now from as little as $1. Thank you.

Donate now
Troy Farah is an independent journalist from Southwest California. His reporting on drug policy and science has appeared in WIRED, The Guardian, Undark, Ars Technica, VICE and more. He co-hosts the drug policy podcast Narcotica. Follow him on Twitter



Watch the Vibrations of Ayahuasca Songs Projected on Water

Contemporary Artist Naziha Mestaoui uses technology to make the invisible visible
How To

What You Need to Know About Smoking Weed While Tripping

A lot of people do it—but should you?
Q & A

MDMA for Racial Trauma

More than 80 percent of participants in psychedelic trials going back to 1993 have been white. Monnica Williams is working to change that.